Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;22(Spec Issue):62-71.

Tranexamic Acid as Antifibrinolytic Agent in Non Traumatic Intracerebral Hemorrhages

Ananda Arumugam  1 , Noor Azman A Rahman  2 , Sharon Casilda Theophilus  2 , Ashraf Shariffudin  2 , Jafri Malin Abdullah  3
Affiliations

Tranexamic Acid as Antifibrinolytic Agent in Non Traumatic Intracerebral Hemorrhages

Ananda Arumugam et al. Malays J Med Sci. 2015 Dec.

Abstract

Background: Mortality and morbidity associated with intracerebral hemorrhage is still high. Up to now, there are no evidence-based effective treatments for acute ICH. This study is to assess the effect of tranexamic acid (TXA) on hematoma growth of patients with spontaneous ICH compared to a placebo.

Methods: We performed a single-blinded, randomised placebo-controlled trial of TXA (intravenous 1g bolus, followed by infusion TXA 1 g/hour for 8 hours) in acute (< 8 hours) primary ICH. Strict blood pressure control (target SBP 140-160 mmHg). A repeat Computed Tomography brain was done after 24 hours to reassess hematoma growth. The primary objective is to test the effect of TXA on hematoma growth. Other objective was to test the feasibility, tolerability, and adverse events of TXA in primary ICH.

Results: Statistical analysis showed significant hematoma growth in control group after 24 hours compared to baseline (14.3300 vs 17.9940, P = 0.001) whereas the treatment group there is no significant hematoma size expansion between baseline and after 24 hours (P = 0.313).

Conclusions: This study showed a significant hematoma volume expansion in the control group compared to the treatment group.

Keywords: antifibrinolytic agents; hypertension; non-traumatic intracerebral bleed; primary hypertensive hemorrhage; tranexamic acid.

PubMed Disclaimer

References

    1. Aguilar MI, Brott TG. Update in intracerebral hemorrhage. Neurohospitalist. 2011;1(3):148–159. doi: 10.1177/1941875211409050 . - PMC - PubMed
    1. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res. 2005;27(3):268–279. doi: http://dx.doi.org/10.1179/016164105X25225 . - PubMed
    1. Balami JS, Buchan AM. Complications of intracerebral haemorrhage. Lancet Neurol. 2012;11(1):101–118. doi: 10.1016/S1474-4422(11)70264-2 . - PubMed
    1. Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl. 1987;137:22–25. - PubMed
    1. Qureshi AI, Hanel RA, Kirmani JF, Yahia Am, Hopkins LN. Cerebral blood flow changes associated with intracerebral hemorrhage. Neurosurg Clin N Am. 2002;13(3):355–370. - PubMed

LinkOut - more resources